UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 255,607 Shares of Baxter International Inc. $BAX

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in shares of Baxter International Inc. (NYSE:BAX) by 14.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,513,888 shares of the medical instruments supplier’s stock after selling 255,607 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Baxter International were worth $32,276,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of BAX. New Mexico Educational Retirement Board increased its stake in Baxter International by 5.8% in the 2nd quarter. New Mexico Educational Retirement Board now owns 25,661 shares of the medical instruments supplier’s stock worth $547,000 after acquiring an additional 1,400 shares during the last quarter. Mufg Securities Americas Inc. grew its holdings in shares of Baxter International by 9.3% in the second quarter. Mufg Securities Americas Inc. now owns 15,556 shares of the medical instruments supplier’s stock worth $332,000 after purchasing an additional 1,320 shares during the last quarter. Hsbc Holdings PLC grew its stake in shares of Baxter International by 11.0% in the second quarter. Hsbc Holdings PLC now owns 691,167 shares of the medical instruments supplier’s stock worth $14,748,000 after purchasing an additional 68,302 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Baxter International by 276.2% in the 2nd quarter. Wellington Management Group LLP now owns 137,400 shares of the medical instruments supplier’s stock worth $2,929,000 after buying an additional 100,875 shares during the last quarter. Finally, Empowered Funds LLC bought a new stake in Baxter International in the second quarter valued at $1,240,000. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Analyst Upgrades and Downgrades

BAX has been the topic of a number of recent research reports. Wells Fargo & Company upped their price objective on shares of Baxter International from $19.00 to $23.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Zacks Research upgraded shares of Baxter International from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. Stifel Nicolaus boosted their target price on shares of Baxter International from $19.00 to $24.00 and gave the company a “hold” rating in a research note on Tuesday, July 28th. Wall Street Zen upgraded Baxter International from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, TD Cowen lifted their price objective on shares of Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a report on Monday, July 27th. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Baxter International presently has an average rating of “Hold” and a consensus price target of $22.45.

Baxter International Trading Down 0.7%

Shares of NYSE:BAX opened at $25.53 on Friday. The company has a market capitalization of $13.20 billion, a PE ratio of -12.33, a PEG ratio of 3.89 and a beta of 0.60. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 1.39. The business has a 50 day moving average of $24.65 and a two-hundred day moving average of $20.68. Baxter International Inc. has a 12-month low of $15.73 and a 12-month high of $30.00.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. The firm had revenue of $2.96 billion during the quarter, compared to analyst estimates of $2.80 billion. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.Baxter International’s revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, analysts forecast that Baxter International Inc. will post 2.04 EPS for the current year.

Baxter International Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be paid a $0.01 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $0.04 dividend on an annualized basis and a yield of 0.2%. Baxter International’s dividend payout ratio (DPR) is currently -1.93%.

Baxter International Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.